ProCE Banner Activity

STIMULUS-AML2: Preliminary Safety of Sabatolimab Monotherapy in Patients With MRD+ AML After AlloSCT

Conference Coverage

Results from the safety run-in of the phase Ib/II STIMULUS-AML2 trial in adults with AML who attained a hematologic CR after allogeneic SCT but who subsequently tested positive for minimal residual disease showed that sabatolimab, a TIM-3 inhibitor, was well tolerated by patients, with some remaining in CR for >1 year.

Released: December 10, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.